Total
0
Shares
TransCanna starts getting social
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicenna Therapeutics (MDNA) has appointed Dr. Kevin Moulder, a veteran in the immunology and oncology industries, as the company's Chief Scientific Officer
  • Dr. Moulder will be a key driver in the development of the company's Superkine and BiSKITs platforms
  • Medicenna is a clinical-stage immunotherapy company focused on the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer
  • Medicenna Therapeutics Corp. (MDNA) is up 0.62 per cent and is trading at  $4.85 per share

Medicenna Therapeutics (MDNA) has appointed Dr. Kevin Moulder as the company's Chief Scientific Officer.

Dr. Moulder, a veteran in the immunology and oncology industries, has over 30 years of experience in drug discovery and development in the fields of protein design, antibody technology, immuno-oncology, inflammation and autoimmune disease.

Dr. Fahar Merchant, President and CEO of Medicenna, commented,

“We are thrilled to welcome Kevin to Medicenna as his scientific and technical expertise will be instrumental in the development of our novel Superkine and BiSKITs™ platforms and while helping to expand our clinical-stage pipeline.”

Dr. Moulder holds a first-class honours degree in biological sciences and a Ph.D. in Immunology from the University of London.

He commented,

“The opportunity to serve as Medicenna’s CSO is truly exciting. The company’s Superkine and BiSKITs™ platforms are powerful tools that have generated potentially first and best-in-class assets designed to overcome the limitations of currently available immunotherapies.”

Medicenna is a clinical-stage immunotherapy company focused on the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer.

Medicenna Therapeutics Corp. (MDNA) is up 0.62 per cent and is trading at  $4.85 per share as of 11:02 am ET.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Avicanna Inc - CEO, Aras Azadian - The Market Herald Canada

" Avicanna (TSX:AVCN) files US patent application for cannabinoid formulation

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.
Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

" Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.